Key Highlights
- Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.
Moderna, Merck Report Positive Results From Cancer-Vaccine Study
Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.
Loading ad...
Loading ad...
Sources
This quick summary is automatically generated using AI based on reports from multiple news sources. The content has not been reviewed or verified by humans. For complete details, accuracy, and context, please refer to the original published articles.
Related Stories
After a year marked by measles outbreaks across the U.S., is the virus now endemic?
Health
January 20, 2026
<strong>The 6 Pieces of Gear Aaron Gordon Can’t Live Without</strong>
Health
January 20, 2026
Collectors told to form JACs to ensure proper hygiene at welfare hostels in Andhra Pradesh
Health
January 20, 2026